Nachrichten zur ANI Pharmaceuticals Inc. Aktie

ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference

PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today…

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

…

ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript

…

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

BAUDETTE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today…

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

…

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

…

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today…

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda

Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory…

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

…

Aresus gibt Strategie zur Erweiterung der Produktionskapazitäten für den pharmazeutischen Wirkstoff Sinecatechins bekannt

Dermago GmbH: Strausberg (ots) - Die Aresus Pharma GmbH, ein Unternehmen der DERMAGO-Gruppe, Deutschland, gibt den Abschluss einer Kooperationsvereinbarung mit…

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today…

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced…

ANI Pharmaceuticals, Alimera Sciences deal set to close Monday

…

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

ANI and Alimera Scheduled the Closing for September 16, 2024 ANI and Alimera Scheduled the Closing for September 16, 2024…

ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today…

NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript

…

Earnings call: ANI Pharmaceuticals reports strong Q2 growth, raises guidance By Investing.com

Earnings call: ANI Pharmaceuticals reports strong Q2 growth, raises guidance…

ANI Pharmaceuticals, Inc. (ANIP) Q2 2024 Earnings Call Transcript

…

ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today…

ANI Pharmaceuticals beats top-line and bottom-line estimates; raises FY24 outlook

…

ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance

BAUDETTE, Minn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today…

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

…

ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.

New York, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates…

Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria

Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) signed a distribution agreement for the Republic of Nigeria that can generate the company €7.9…

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has…

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today…

Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals

Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is…

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

Conference call scheduled for today at 8:30 a.m. ET…

Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…

Implied Volatility Surging for ANI Pharmaceuticals (ANIP) Stock Options

Investors need to pay close attention to ANI Pharmaceuticals (ANIP) stock based on the movements in the options market lately.…

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

…

Global Dyspepsia Drugs Market Size To Worth Exceed USD 14.7 Billion By 2033 | CAGR Of 4.46%

The Global Dyspepsia Drugs Market Size was Valued at USD 9.5 Billion in 2023 and the Worldwide Dyspepsia Drugs Market…

ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference

BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today…

NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript

…

ANI Pharmaceuticals, Inc. (ANIP) Q1 2024 Earnings Call Transcript

…

Nika Pharmaceuticals, Inc. (NIKA) Acquires a Two Million USD Production Building

Nika Pharmaceuticals, Inc. (NIKA) acquired production building and land valued at $2,045,209 and signed a supply agreement for vial production…

ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance

BAUDETTE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today…

ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: Whats in Store?

ANI Pharmaceuticals (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of…

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today…

Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement

Nika Pharmaceuticals, Inc. (NKPH) announces the purchase of technologies for production of three generic drugs in tablet form and one…

GMAB: 3 Biotech Stocks Gaining Altitude and Interest

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy…

Nika Pharmaceuticals, Inc. (NKPH) Merges With Nika Biotechnology, Inc.

Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.…

ANI Pharmaceuticals, Inc. (ANIP) Q4 2023 Earnings Call Transcript

…

ANI Pharmaceuticals to present at Leerink Biopharma Conference By Investing.com

ANI Pharmaceuticals to present at Leerink Biopharma Conference…

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Call Transcript

…

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today…

ANI Pharmaceuticals: A New Assessment

…

BUSINESS WIRE: Nordic Pharma Group B.V. schließt über ihre Tochtergesellschaft Amring Pharmaceuticals Inc. die Übernahme von Visant Medical ab, um in den Vereinigten Staaten eine neuartige Therapie für trockene Augen einzuführen

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.BERWYN, Pennsylvania --(BUSINESS WIRE)-- 18.12.2023 --Amring Pharmaceuticals…

Branded Legacy, Inc. (BLEG) Expands Portfolio with Comprehensive Acquisition of MariJ Pharmaceuticals Inc, Including Licenses, Organic Certifications, and Substantial Assets

Acquisition marks the largest acquisition to date with multi-state processing licenses, compounding pharmacy license, and advanced equipment Acquisition marks the…

Global Non-Hodgkin Lymphoma Therapeutics Market Size To Worth USD 16.64 Billion by 2032 | CAGR of 7.8%

The Global Non-Hodgkin Lymphoma Therapeutics Market Size was valued at USD 7.85 Billion in 2022. The Worldwide Non-Hodgkin Lymphoma Therapeutics…